VivoSeq
Other

H Pylori Infection

0

Pipeline Programs↗

3

Active Trials↗

1

Companies Involved↗

H Pylori Infection is an early-stage landscape with 0 programs across 1 company. The most active players are TenNor Therapeutics (Suzhou) Limited.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

93/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

TenNor Therapeutics (Suzhou) Limited

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

25

clinical trials

Completed14 · 56%
Unknown status7 · 28%
Not yet recruiting2 · 8%
Terminated1 · 4%
Recruiting1 · 4%

Clinical Trials

Trial Activity

25 trials

Susceptibility Testing Guided Versus Empirical Therapy for Refractory H. Pylori Infection
Recruiting·NNational Taiwan University Hospital·Phase 4·NCT04332848·360 enrolled
Comparison of Omeprazole vs Vonoprazon in Treatment of H Pylori Infection
Not yet recruiting·RRehman Medical Institute - RMI·Phase 4·NCT07040839·128 enrolled
Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection
Not yet recruiting·TTanta University·Phase 3·NCT07275827·88 enrolled
Sequential Therapy Versus Quadruple Therapy as Second Line Treatment After Failure of the Standard Triple Therapy for H Pylori Infection
Completed·SSoroka University Medical Center·Phase 3·NCT01481844·101 enrolled
High Dose Dual Therapy vs Clarithromycin Triple Therapy for Treatment Naive H Pylori Infection in an Urban Population
Completed·IIcahn School of Medicine at Mount Sinai·Phase 4·NCT05342532·112 enrolled
The Effect of H. Pylori Infection on Iron Metabolism
Completed·SSeattle Institute for Biomedical and Clinical Research·Phase 2/3·NCT00202488·39 enrolled
Levofloxacin Triple and Bismuth Quadruple Therapies for Rescue Treatment of H Pylori Infection
Completed·KKaohsiung Veterans General Hospital.·N/A·NCT02978157·102 enrolled
Sequential and Hybrid Therapies for H Pylori Infection
Completed·KKaohsiung Veterans General Hospital.·Phase 4·NCT01085786·240 enrolled
Personalized Treatment for Refractory H Pylori Infection
Completed·KKaohsiung Veterans General Hospital.·N/A·NCT02547025·126 enrolled
Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection
Completed·TTenNor Therapeutics (Suzhou) Limited·Phase 3·NCT05857163·700 enrolled
5 Day Concomitant Versus 10 Day Sequential Therapy for Eradication of H. Pylori Infection
Completed·UUniversity of Campania Luigi Vanvitelli·Phase 3·NCT01544517·180 enrolled
Mixed Strain H. Pylori Infection in Patients Who Have Problems With Eradication of H. Pylori
Completed·UUniversity Medical Centre Ljubljana·N/A·NCT01164969·10 enrolled
Concomitant, Sequential, and Standard Triple Therapy for H. Pylori Infection
Completed·KKaohsiung Veterans General Hospital.·Phase 4·NCT01769365·307 enrolled
Eradication of H. Pylori Infection With Moxifloxacin
Completed·IIyad Naeem Muhammad, PhD·Phase 3·NCT05863858·162 enrolled
Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding"
Completed·—·Phase 3·NCT07487142·121 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)